Robust Inference in Discrete Hazard Models for Randomized Clinical Trials
Overview
Authors
Affiliations
Time-to-event data in which failures are only assessed at discrete time points are common in many clinical trials. Examples include oncology studies where events are observed through periodic screenings such as radiographic scans. When the survival endpoint is acknowledged to be discrete, common methods for the analysis of observed failure times include the discrete hazard models (e.g., the discrete-time proportional hazards and the continuation ratio model) and the proportional odds model. In this manuscript, we consider estimation of a marginal treatment effect in discrete hazard models where the constant treatment effect assumption is violated. We demonstrate that the estimator resulting from these discrete hazard models is consistent for a parameter that depends on the underlying censoring distribution. An estimator that removes the dependence on the censoring mechanism is proposed and its asymptotic distribution is derived. Basing inference on the proposed estimator allows for statistical inference that is scientifically meaningful and reproducible. Simulation is used to assess the performance of the presented methodology in finite samples.
Causal interpretation of the hazard ratio in randomized clinical trials.
Fay M, Li F Clin Trials. 2024; 21(5):623-635.
PMID: 38679930 PMC: 11502288. DOI: 10.1177/17407745241243308.
Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic.
Meyer R, Ratitch B, Wolbers M, Marchenko O, Quan H, Li D Stat Biopharm Res. 2021; 12(4):399-411.
PMID: 34191971 PMC: 8011486. DOI: 10.1080/19466315.2020.1779122.
Nguyen V, Gillen D Stat Biosci. 2020; 9(2):406-430.
PMID: 32190128 PMC: 7079760. DOI: 10.1007/s12561-016-9162-z.
Joeng H, Chen M, Kang S Lifetime Data Anal. 2015; 22(1):38-62.
PMID: 25772374 PMC: 4676960. DOI: 10.1007/s10985-015-9326-z.